| Source: | Semisynthetic derivate of Staurosporine. Made from Staurosporine from Streptomyces staurosporeus
|
| Synonyms |
Midostaurin, Benzoylstaurosporine, 4'-N-Benzoylstaurosporine, CGP 41251 |
| Description: | PKC412 (Midostaurin) is a cell permeable inhibitor of protein kinases, including protein kinase-C. |
| CAS number: | 120685-11-2 |
| Merck index: | 14:6185 |
| Molecular weight: | 570.6 |
| Structure: | 
 |
| Molecular Formula: | C35H30N4O4 |
| Canonical SMILES: |
|
Solubility
information: | Soluble in DMSO, Dichloromethanol
water solubility : < 0.1 mg/1 |
| Specifications | |
| Appearance: | White to off-white powder |
| Purity: | Not less than 96% by HPLC, TLC Current lot: 98.96% by HPLC |
| λmax: | 241, 292, 334, 370 nm |
| Melting point | 225-235ºC |
| Solubility | Clear colorless solution at 10mg/ml DMSO / 10mg/ml MDC / 5mg/ml methanol |
| Storage | -20ºC. Protect from moisture and direct light. |
| Applications | PKC412 is mentioned as a specific treatment for Myeloproliferative Disease (MPD) PKC412 selectively inhibits protein kinase C (PKC), |
| Classification |
indolocarbazole alkaloid
PKC inhibitor |
| Warnings |
May be irritating to eyes, skin and respiratory system |
| Related products |
KT5853 , KT5720 , staurosporine , PKC412
K252a , K252B K252c
|
| | For Research use only. Not for Human or Drug use
GMP/API grade available on request
No genetically modified organisms are used. |
| Publications | Li H, Hergert SM, Schäfer SC, Brausch I, Yao Y, Huang Q, Mang C, Lehr HA, Förstermann U.
Nitric Oxide. 2005 Jun;12(4):231-6.
Midostaurin (PKC412) upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse. |
| | Millward MJ, House C, Bowtell D, Webster L, Olver IN, Gore M, Copeman M, Lynch K, Yap A, Wang Y, Cohen PS, Zalcberg J.
Br J Cancer. 2006 Oct 9;95(7):829-34
The multikinase inhibitor midostaurin (PKC412) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. |
| | Barry EV, Clark JJ, Cools J, Roesel J, Gilliland DG.
Blood. 2007 Dec 15;110(13):4476-9
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin (PKC412). |
|
|
